Diabetes and everolimus-eluting stents: what we know and what is still missing. Insights from subanalysis of the SORT OUT IV trial.
Percutaneous coronary interventions in diabetic patients are still challenging in the drug-eluting stents era because of the more extensive coronary artery disease and the presence of comorbidities. New-generation drug-eluting stents have demonstrated an improved efficacy and safety in patients treated with percutaneous coronary interventions. The SORT OUT IV substudy has investigated the clinical impact of the everolimus-eluting stents versus sirolimus-eluting stents in both the diabetic and nondiabetic population.